Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Michael Berger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Maryam B. Lustberg(Yale Cancer Center), Craig Vargo(University of Pisa), Ewa Mrózek(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Erin Macrae(McGill University), Charles L. Shapiro(Tisch Hospital), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Bhuvaneswari Ramaswamy(The Ohio State University), Katy Shaver(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Robert Wesolowski(The Ohio State University Wexner Medical Center), Gary Phillips(The Ohio State University), M J Vincent(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 29
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study
|The Lancet Infectious Diseases|2012|554